$4500 | Single User
$6300 | Site License
$9000 | Enterprise License

Nuclear Medicine/Radiopharmaceutical Global Market – Forecast To 2022
[Report Updated: 24-03-2016]

Published by IQ4I: 24 Mar 2016 | 111553 | In Stock
Related Topics: Healthcare

Introduction

Way back to the history, over the past 50 years nuclear medicine sector has displayed a strong link between investments in chemistry and development of radionuclide’s and radiolabeled compounds. This advancement has majorly impacted the health care practice. In the present scenario nuclear medicine is considered to be one of the diagnostics and therapeutic modality technique for probing, tracking and treating disease-related tissue function, progression and treatment response. Non-invasive nuclear medicine imaging technique provides functional information at both molecular and cellular level and helps measuring the uptake and turnover of target-specific radiotracers in tissue.

Radioisotopes are used in a wide variety of applications like oncology, cardiovascular and neurological disorders. But in recent times, advancements in the field of nuclear medicine and radioactive tracers have emerged to provide few practical methods for studying the limited metabolic activities of bones and teeth, hence has found a role in dental science research.

According to IQ4I analysis, the global nuclear medicine/radiopharmaceutical market is expected to reach 9,275.3 million by 2022. Nuclear medicinal market is mainly classified into type (diagnosis & therapeutics), application and end-users. The global nuclear medicine market by diagnosis is further divided into SPECT and PET while therapeutics market is segmented into alpha radiation therapy, beta radiation therapy and brachytherapy.

The SPECT and PET diagnostics market is further divided into isotopes and application. SPECT market by isotopes includes technetium (Tc-99m), thallium (Tl-201), gallium (Ga-67), iodine (I-123), samarium (Sm-153), yttrium (Y-90), rhenium (Re-186) and others. SPECT by applications are classified into cardiology, gastro intestinal, oncology, nephrology, neurology, inflammation, thyroid glands, lymphology and others. The PET diagnostic market by isotopes involves fluorodeoxyglucose (18f-FDG), gallium (Ga-68), rubidium (Rb-82) and others. PET applications are segmented into cardiology, oncology, neurology, inflammation, thyroid and others.

The alpha radiation therapy includes actinium (Ac-225), astatine-211 (At-211), lead (Pb-212)/bismuth (Bi-212), radium (Ra-223), radium-224 (Ra-224), thorium-227 (Th-227) and others. The isotopes considered in beta radiation therapy are erbium (Er-169), iodine (I-131) lutetium (Lu-177), rhenium (Re-186), samarium (Sa-153), strontium (Sr-89), yttrium (Y-90) and others. The final therapeutic segment brachytherapy involves cesium (Cs-131), iodine (I-125), iridium (Ir-192), palladium (Pd-103) and others

The nuclear medicine market end-users include medical, academic research laboratories and industries. The end-users by medical further segmented into hospitals and diagnostic centers.

The nuclear medicine/radiopharmaceutical market includes stable isotopes section as well which is classified into isotopes and applications. Isotopes considered are carbon (C-13), deuterium (D2), oxygen (O-18), nitrogen (N-15), sulphur (S-32) and others. The stable isotopes have application in diagnostics and therapy, pharmaceutical companies, research section and industrial sector. The leading players of this market are Cambridge Isotope Laboratories (U.S) and Isotec Inc. subsidiary of Sigma Aldrich (U.S.).

The nuclear medicine/radiopharmaceuticals market is expected to grow at single digit CAGR during 2015 to 2022. The factors driving the growth of this market are increased application of radiopharmaceuticals, rise in public awareness, usage of hybrid imaging, abundance of radio pharmaceuticals, technological advancements; alpha radio immunotherapy based targeted cancer treatment and wide range of available products likely to propel the nuclear medicine market. In addition to this, increasing need in emerging markets, production of radio pharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes, increasing therapeutic application areas and replacement of old/traditional equipment are some of the opportunities that are propelling the growth of the market. However, regulatory issues, high cost and supply shortage of isotopes, shorter half life of radiopharmaceuticals, and threat from traditional/alternative diagnostic procedures are hampering the growth of the market. The threats for the nuclear medicine/radiopharmaceuticals market include huge capital investment and shortage of qualified technicians. The major problem area of nuclear medicine market is closure of reactors.

The nuclear medicine/radiopharmaceuticals global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Some of the key players of the nuclear medicine market are Bayer Healthcare (Germany) Cardinal Health Inc. (U.S.), Cambridge Isotope Laboratories (U.S), GE Healthcare (U.K.), IBA Group (Belgium), Isotec Inc. (U.S.) Lantheus Medical Imaging (U.S.), Mallinckrodt Plc (Ireland), NTP Radioisotopes (South Africa), Nordion Inc (Canada) Siemens Healthcare (Germany) and Taiyo Nippon Sanso Corporation (Japan).

The report provides an in depth market analysis of the above mentioned segments across the following regions:

• North America

• Europe

• Asia-Pacific

• Rest of the World (RoW)

Table of Contents
for Nuclear Medicine/Radiopharmaceutical Global Market – Forecast To 2022 [Report Updated: 24-03-2016]

  • 1 EXECUTIVE SUMMARY 35

    2 INTRODUCTION 40

    2.1 KEY TAKE AWAYS 40

    2.2 REPORT DESCRIPTION 41

    2.3 MARKETS COVERED 44

    2.4 STAKEHOLDERS 47

    2.5 RESEARCH METHODOLOGY 47

    2.5.1 MARKET SIZE ESTIMATION 49

    2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION 51

    2.5.3 SECONDARY SOURCES 52

    2.5.4 KEY DATA POINTS FROM SECONDARY SOURCES 53

    2.5.5 PRIMARY SOURCES 54

    2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 54

    2.5.7 ASSUMPTIONS 54

    3 MARKET ANALYSIS 56

    3.1 INTRODUCTION 56

    3.2 MARKET SEGMENTATION 57

    3.3 FACTORS INFLUENCING MARKET 60

    3.3.1 DRIVERS & OPPORTUNITIES 61

    3.3.1.1 Increased application of radio pharmaceuticals 61

    3.3.1.2 Rise in public awareness 62

    3.3.1.3 Usage of hybrid imaging 62

    3.3.1.4 Abundance of radio pharmaceuticals 63

    3.3.1.5 Technological advancements 63

    3.3.1.6 Increasing need in emerging markets 64

    3.3.1.7 Production of radio pharmaceuticals from cyclotrons 65

    3.3.1.8 Efficient diagnosis and treatments 65

    3.3.1.9 Emerging radioisotopes 66

    3.3.1.10 Increasing therapeutic application areas 66

    3.3.1.11 Replacement of old/traditional equipment 67

    3.3.2 RESTRAINTS & THREATS 67

    3.3.2.1 Regulatory issues 67

    3.3.2.2 High cost and supply shortage of isotopes 68

    3.3.2.3 Shorter half-life of radiopharmaceuticals 69

    3.3.2.4 Threat from traditional/alternative diagnostic procedures 69

    3.3.2.5 Huge capital investment 70

    3.3.2.6 Shortage of qualified technicians 70

    3.3.2.7 Radio toxicity 71

    3.4 PROBLEM AREAS 72

    3.4.1 CLOSURE OF REACTORS 72

    3.5 WINNING IMPERATIVES 72

    3.5.1 AVAILABILITY OF TECHNETIUM 72

    3.6 REGULATORY GUIDELINES 73

    3.6.1 UNITED STATES 73

    3.6.2 EUROPE 74

    3.6.3 JAPAN 74

    3.6.4 CHINA 75

    3.6.5 SOUTH KOREA 76

    3.7 REIMBURSEMENT SCENARIO & CHALLENGES 76

    3.8 PATENT TRENDS 88

    3.9 SUPPLY CHAIN ANALYSIS 91

    3.9.1 REACTORS 91

    3.9.2 PROCESSING FACILITY 92

    3.9.3 GENERATORS MANUFACTURING UNITS 93

    3.9.4 HOSPITALS AND CENTRAL RADIO PHARMACIES 93

    3.10 LIST OF POTENTIAL NEW REACTORS 94

    3.11 PORTER'S FIVE FORCE ANALYSIS 96

    3.11.1 THREAT OF NEW ENTRANTS 96

    3.11.2 THREAT OF SUBSTITUTES 97

    3.11.3 BARGAINING POWER OF SUPPLIERS 97

    3.11.4 BARGAINING POWER OF BUYERS 97

    3.11.5 COMPETITIVE RIVALRY 98

    3.12 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 99

    3.12.1 NUCLEAR MEDICINE MARKET 99

    3.12.2 STABLE ISOTOPES MARKET 102

    4 RADIOPHARMACEUTICALS BY TYPE 104

    4.1 INTRODUCTION 104

    4.2 DIAGNOSTICS 106

    4.2.1 RADIOPHARMACEUTICALS FOR DIAGNOSIS, BY ISOTOPES 111

    4.2.1.1 SPECT, by isotopes 111

    4.2.1.1.1 Technetium (Tc-99m) 114

    4.2.1.1.2 Thallium (Tl-201) 116

    4.2.1.1.3 Gallium (Ga-67) 118

    4.2.1.1.4 Iodine (I-123) 119

    4.2.1.1.5 Samarium (Sm-153) 121

    4.2.1.1.6 Yttrium (Y-90) 122

    4.2.1.1.7 Rhenium (Re-186) 124

    4.2.1.1.8 Others 125

    4.2.1.2 PET, by isotopes 127

    4.2.1.2.1 Fluorodeoxyglucose (FDG) 128

    4.2.1.2.2 Gallium (Ga-68) 130

    4.2.1.2.3 Rubidium (Rb-82) 133

    4.2.1.2.4 Others 134

    4.2.2 RADIOPHARMACEUTICALS FOR DIAGNOSIS, BY APPLICATION 136

    4.2.2.1 SPECT by application 136

    4.2.2.1.1 Cardiology 138

    4.2.2.1.2 Gastro intestinal 140

    4.2.2.1.3 Oncology 141

    4.2.2.1.4 Nephrology 143

    4.2.2.1.5 Neurology 144

    4.2.2.1.6 Inflammation 145

    4.2.2.1.7 Thyroid glands 146

    4.2.2.1.8 Lymphology 148

    4.2.2.1.9 Others 149

    4.2.2.2 PET by application 151

    4.2.2.2.1 Oncology 152

    4.2.2.2.2 Neurology 153

    4.2.2.2.3 Cardiology 155

    4.2.2.2.4 Inflammation 156

    4.2.2.2.5 Others 157

    4.3 THERAPEUTICS 159

    4.3.1 RADIOPHARMACEUTICALS FOR THERAPEUTICS, BY TYPE 160

    4.3.1.1 Beta radiation therapy 162

    4.3.1.1.1 Yttrium (Y-90) 165

    4.3.1.1.2 Iodine (I-131) 167

    4.3.1.1.3 Lutetium (Lu-177) 169

    4.3.1.1.4 Samarium (Sm-153) 171

    4.3.1.1.5 Rhenium (Re-186) 173

    4.3.1.1.6 Strontium (Sr-89) 175

    4.3.1.1.7 Erbium (Er-169) 177

    4.3.1.1.8 Others 179

    4.3.1.2 Alpha radiation therapy, by isotopes 181

    4.3.1.2.1 Actinium (Ac-225) 182

    4.3.1.2.2 Astatine (At-211) 182

    4.3.1.2.3 Lead (Pb-212)/Bismuth (Bi-212) 183

    4.3.1.2.4 Radium-224 183

    4.3.1.2.5 Radium-223 184

    4.3.1.2.6 Thorium-227 (Th-227) 184

    4.3.1.2.7 Others 185

    4.3.1.3 Brachytherapy, by isotopes 186

    4.3.1.3.1 Iodine (I-125) 189

    4.3.1.3.2 Cesium (Cs-131) 191

    4.3.1.3.3 Iridium (Ir-192) 193

    4.3.1.3.4 Palladium (Pd-103) 195

    4.3.1.3.5 Others 197

    4.3.2 Therapeutics radiopharmaceuticals, by application 198

    4.3.2.1 Oncology 200

    4.3.2.2 Nephrology 202

    4.3.2.3 Cardiology 204

    4.3.2.4 Neurology 205

    4.3.2.5 Others 207

    5 GLOBAL NUCLEAR MEDICINE MARKET BY END-USERS 209

    5.1 INTRODUCTION 209

    5.2 MEDICAL 213

    5.2.1 HOSPITALS 214

    5.2.2 DIAGNOSTIC CENTERS 216

    5.3 ACADEMIC RESEARCH LABORATORIES 218

    5.4 INDUSTRIES 220

    6 STABLE ISOTOPES 222

    6.1 INTRODUCTION 222

    6.2 MARKET ANALYSIS 223

    6.2.1 FACTORS INFLUENCING MARKET 223

    6.2.2 DRIVERS & OPPORTUNITIES 224

    6.2.2.1 Increased use as controlled drug standards 224

    6.2.2.2 Increasing medical applications (diagnostics & therapeutics) 224

    6.2.2.3 Increased usage in personalized medicine & PK studies 224

    6.2.2.4 System biology and proteomics applications 225

    6.2.2.5 Ecological and environmental studies 225

    6.2.3 RESTRAINTS AND THREATS 225

    6.2.3.1 High cost of stable isotopes 225

    6.2.3.2 Stable isotopes-side effects 226

    6.2.3.3 Safety issues of deuterium 226

    6.3 STABLE ISOTOPES MARKET, BY ISOTOPE 227

    6.3.1 Carbon (C-13) 230

    6.3.2 Deuterium (D2) 232

    6.3.3 Oxygen (O-18) 234

    6.3.4 Nitrogen (N-15) 236

    6.3.5 Sulfur (S-32) 238

    6.3.6 Others 239

    6.4 STABLE ISOTOPES MARKET, BY APPLICATION 241

    6.4.1 DIAGNOSTICS AND THERAPY 243

    6.4.2 PHARMACEUTICALS 245

    6.4.3 RESEARCH 247

    6.4.4 INDUSTRIAL SECTOR 249

    6.5 STABLE ISOTOPES MARKET, BY GEOGRAPHY 251

    6.5.1 INTRODUCTION 251

    6.5.2 NORTH AMERICA 253

    6.5.3 EUROPE 257

    6.5.4 ASIA-PACIFIC 261

    6.5.5 REST OF THE WORLD 265

    7 REGIONAL ANALYSIS 269

    7.1 INTRODUCTION 269

    7.2 NORTH AMERICA 272

    7.3 EUROPE 289

    7.4 ASIA-PACIFIC 306

    7.5 REST OF THE WORLD 323

    8 COMPETITIVE LANDSCAPE 340

    8.1 INTRODUCTION 340

    8.2 NEW PRODUCT LAUNCHES 341

    8.3 AGREEMENTS, PARTNERSHIP, COLLABORATION & JOINT VENTURES 346

    8.4 APPROVALS 354

    8.5 EXPANSIONS 357

    8.6 MERGERS & ACQUISITIONS 358

    8.7 OTHER DEVELOPMENTS 361

    9 MAJOR PLAYER PROFILES 363

    9.1 BAYER HEALTHCARE 363

    9.1.1 OVERVIEW 363

    9.1.2 FINANCIALS 364

    9.1.3 PRODUCT PORTFOLIO 367

    9.1.4 KEY DEVELOPMENTS 367

    9.1.5 BUSINESS STRATEGY 368

    9.1.6 SWOT ANALYSIS 369

    9.2 CARDINAL HEALTH INC. 370

    9.2.1 OVERVIEW 370

    9.2.2 FINANCIALS 371

    9.2.3 PRODUCT PORTFOLIO 374

    9.2.4 KEY DEVELOPMENTS 375

    9.2.5 BUSINESS STRATEGY 377

    9.2.6 SWOT ANALYSIS 378

    9.3 CAMBRIDGE ISOTOPE LABORATORIES INC. 379

    9.3.1 OVERVIEW 379

    9.3.2 FINANCIALS 379

    9.3.3 PRODUCT PORTFOLIO 380

    9.3.4 KEY DEVELOPMENTS 381

    9.3.5 BUSINESS STRATEGY 382

    9.3.6 SWOT ANALYSIS 383

    9.4 GE HEALTHCARE 384

    9.4.1 OVERVIEW 384

    9.4.2 FINANCIALS 385

    9.4.3 PRODUCT PORTFOLIO 388

    9.4.4 KEY DEVELOPMENTS 388

    9.4.5 BUSINESS SRATEGY 391

    9.4.6 SWOT ANALYSIS 392

    9.5 IBA GROUP 393

    9.5.1 OVERVIEW 393

    9.5.2 FINANCIALS 394

    9.5.3 PRODUCT PORTFOLIO 397

    9.5.4 KEY DEVELOPMENTS 398

    9.5.5 BUSINESS STRATEGY 399

    9.5.6 SWOT ANALYSIS 400

    9.6 ISOTEC INC 401

    9.6.1 OVERVIEW 401

    9.6.2 FINANCIALS 402

    9.6.3 PRODUCT PORTFOLIO 404

    9.6.4 KEY DEVELOPMENTS 406

    9.6.5 BUSINESS STRATEGY 407

    9.6.6 SWOT ANALYSIS 408

    9.7 LANTHEUS MEDICAL IMAGING INC. 409

    9.7.1 OVERVIEW 409

    9.7.2 FINANCIALS 410

    9.7.3 PRODUCT PORTFOLIO 413

    9.7.4 KEY DEVELOPMENTS 413

    9.7.5 BUSINESS STRATEGY 415

    9.7.6 SWOT ANALYSIS 416

    9.8 MALLINCKRODT PLC 417

    9.8.1 OVERVIEW 417

    9.8.2 FINANCIALS 418

    9.8.3 PRODUCT PORTFOLIO 420

    9.8.4 KEY DEVELOPMENTS 421

    9.8.5 BUSINESS STRATEGY 423

    9.8.6 SWOT ANALYSIS 424

    9.9 NORDION INC 425

    9.9.1 OVERVIEW 425

    9.9.2 FINANCIALS 425

    9.9.3 PRODUCT PORTFOLIO 426

    9.9.4 KEY DEVELOPMENTS 427

    9.9.5 BUSINESS STRATEGY 428

    9.9.6 SWOT ANALYSIS 429

    9.10 NTP RADIOISOTOPES SOC LTD 430

    9.10.1 OVERVIEW 430

    9.10.2 FINANCIALS 430

    9.10.3 PRODUCT PORTFOLIO 431

    9.10.4 KEY DEVELOPMENTS 432

List Of Tables
in Nuclear Medicine/Radiopharmaceutical Global Market – Forecast To 2022 [Report Updated: 24-03-2016]

LIST OF TABLES


TABLE 1 NUCLEAR MEDICINE GLOBAL MARKET REVENUE BY REGION,

(2014-2022) ($MN) 39

TABLE 2 REIMBURSEMENT RATES FOR BONE SCANS IN UNITED STATES 78

TABLE 3 REIMBURSEMENT RATES FOR RADIOPHARMACEUTICALS AND DIAGNOSTIC IMAGING TECHNIQUES 79

TABLE 4 TECHNETIUM (TC-99M) REACTORS 92

TABLE 5 NEW POTENTIAL REACTORS 95

TABLE 6 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY TYPE,

(2014-2022) ($MN) 106

TABLE 7 NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 108

TABLE 8 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 109

TABLE 9 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 110

TABLE 10 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY ISOTOPE,

(2014-2022) ($MN) 113

TABLE 11 SPECT TECHNETIUM (TC-99M) ISOTOPE GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 116

TABLE 12 SPECT THALLIUM (TL-201) ISOTOPE GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 117

TABLE 13 SPECT GALLIUM (GA-67) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 119

TABLE 14 SPECT IODINE (I-123) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 120

TABLE 15 SPECT SAMARIM (SM-153) ISOTOPE GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 122

TABLE 16 SPECT YTTRIUM (Y-90) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 123

TABLE 17 SPECT RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 125

TABLE 18 SPECT OTHER ISOTOPES GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 126

TABLE 19 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY ISOTOPES,

(2014-2022) ($MN) 128

TABLE 20 PET FLUORODEOXYGLUCOSE (18F-FDG) GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 130

TABLE 21 PET GALLIUM (GA-68) GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 132

TABLE 22 PET RUBIDIUM (RB-82) GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 134

TABLE 23 PET OTHER ISOTOPES GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 135

TABLE 24 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 137

TABLE 25 SPECT CARDIOLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 139

TABLE 26 SPECT GASTROINTESTINAL APPLICATION GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 141

TABLE 27 SPECT ONCOLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 142

TABLE 28 SPECT NEPHROLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 143

TABLE 29 SPECT NEUROLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 145

TABLE 30 SPECT INFLAMMATION APPLICATION GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 146

TABLE 31 SPECT THYROID GLANDS APPLICATION GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 147

TABLE 32 SPECT LYMPHOLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 148

TABLE 33 SPECT OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 150

TABLE 34 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 152

TABLE 35 PET ONCOLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 153

TABLE 36 PET NEUROLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 154

TABLE 37 PET CARDIOLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 156

TABLE 38 PET INFLAMMATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 157

TABLE 39 PET INFLAMMATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 158

TABLE 40 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 161

TABLE 41 BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 163

TABLE 42 BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BY ISOTOPES, (2014-2022) ($MN) 164

TABLE 43 BETA RADIATION THERAPY YTTRIUM (Y-90) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 166

TABLE 44 BETA RADIATION THERAPY IODINE(I-131) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 168

TABLE 45 BETA RADIATION THERAPY LUTETIUM (LU-177) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 170

TABLE 46 BETA RADIATION THERAPY SAMARIUM (SM-153) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 172

TABLE 47 BETA RADIATION THERAPY RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 174

TABLE 48 BETA RADIATION THERAPY STRONTIUM (SR-89) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 176

TABLE 49 BETA RADIATION THERAPY ERBIUM (ER-169) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 178

TABLE 50 BETA RADIATION THERAPY OTHER ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 180

TABLE 51 ALPHA RADIATION THERAPY GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 181

TABLE 52 BRACHYTHERAPY GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 187

TABLE 53 BRACHYTHERAPY GLOBAL MARKET REVENUE, BY ISOTOPES,

(2014-2022) ($MN) 188

TABLE 54 BRACHYTHERAPY IODINE (I-125) ISOTOPE GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 190

TABLE 55 BRACHYTHERAPY CESIUM (CS-131) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 192

TABLE 56 BRACHYTHERAPY IRIDIUM (IR-192) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 194

TABLE 57 BRACHYTHERAPY PALLADIUM (PD-103) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 196

TABLE 58 BRACHYTHERAPY OTHER ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 197

TABLE 59 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY APPLICATION,

(2014-2022) ($MN) 199

TABLE 60 NUCLEAR MEDICINE THERAPEUTICS ONCOLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 201

TABLE 61 NUCLEAR MEDICINE THERAPEUTICS NEPHROLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 203

TABLE 62 NUCLEAR MEDICINE THERAPEUTICS CARDIOLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 204

TABLE 63 NUCLEAR MEDICINE THERAPEUTICS NEUROLOGY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 206

TABLE 64 NUCLEAR MEDICINE THERAPEUTICS OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 208

TABLE 65 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY END-USERS,

(2014-2022) ($MN) 211

TABLE 66 NUCLEAR MEDICINE (MEDICAL) END-USERS GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 212

TABLE 67 NUCLEAR MEDICINE (MEDICAL) END-USERS GLOBAL MARKET REVENUE,

BY TYPE, (2014-2022) ($MN) 214

TABLE 68 NUCLEAR MEDICINE HOSPITAL END-USERS GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 215

TABLE 69 NUCLEAR MEDICINE DIAGNOSTIC CENTRES END-USER GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 217

TABLE 70 NUCLEAR MEDICINE ACADEMIC RESEARCH LABORATORIES END-USER GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 219

TABLE 71 NUCLEAR MEDICINE INDUSTRIES END-USER GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 221

TABLE 72 STABLE ISOTOPES GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 228

TABLE 73 STABLE ISOTOPES GLOBAL MARKET REVENUE, BY ISOTOPE,

(2014-2022) ($MN) 229

TABLE 74 STABLE ISOTOPES CARBON (C-13) GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 231

TABLE 75 STABLE ISOTOPES DEUTERIUM (D2) GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 233

TABLE 76 STABLE ISOTOPES OXYGEN (O-18) GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 235

TABLE 77 STABLE ISOTOPES NITROGEN (N-15) GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 237

TABLE 78 STABLE ISOTOPES SULFUR (S-32) GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 238

TABLE 79 STABLE OTHER ISOTOPES GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 240

TABLE 80 STABLE ISOTOPES GLOBAL MARKET REVENUE, BY APPLICATION,

(2014-2022) ($MN) 242

TABLE 81 STABLE ISOTOPES DIAGNOSTICS &THERAPY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 244

TABLE 82 STABLE ISOTOPES PHARMACEUTICALS APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 246

TABLE 83 STABLE ISOTOPES RESEARCH APPLICATION GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 248

TABLE 84 STABLE ISOTOPES INDUSTRIAL SECTOR APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 250

TABLE 85 STABLE ISOTOPES INDUSTRIAL SECTOR APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 252

TABLE 86 NORTH AMERICAN STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 255

TABLE 87 NORTH AMERICAN STABLE ISOTOPES MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 256

TABLE 88 EUROPEAN STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE,

(2014-2022) ($MN) 259

TABLE 89 EUROPEAN STABLE ISOTOPES MARKET REVENUE, BY APPLICATION,

(2014-2022) ($MN) 260

TABLE 90 ASIA-PACIFIC STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE,

(2014-2022) ($MN) 263

TABLE 91 ASIA-PACIFIC STABLE ISOTOPES MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 264

TABLE 92 REST OF THE WORLD STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 267

TABLE 93 REST OF THE WORLD STABLE ISOTOPES MARKET REVENUE,

BY APPLICATION, (2014-2022) ($MN) 268

TABLE 94 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 271

TABLE 95 NORTH AMERICAN NUCLEAR MEDICINE MARKET REVENUE, BY TYPE,

(2014-2022) ($MN) 277

TABLE 96 NORTH AMERICAN NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 278

TABLE 97 NORTH AMERICAN NUCLEAR MEDICINE SPECT MARKET REVENUE,

BY ISOTOPE, (2014-2022) ($MN) 279

TABLE 98 NORTH AMERICAN NUCLEAR MEDICINE PET MARKET REVENUE,

BY ISOTOPE, (2014-2022) ($MN) 280

TABLE 99 NORTH AMERICAN NUCLEAR MEDICINE SPECT MARKET REVENUE,

BY APPLICATION, (2014-2022) ($MN) 281

TABLE 100 NORTH AMERICAN NUCLEAR MEDICINE PET MARKET REVENUE,

BY APPLICATION, (2014-2022) ($MN) 282

TABLE 101 NORTH AMERICAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 283

TABLE 102 NORTH AMERICAN NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 284

TABLE 103 NORTH AMERICAN NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 285

TABLE 104 NORTH AMERICAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 286

TABLE 105 NORTH AMERICAN NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS, (2014-2022) ($MN) 287

TABLE 106 NORTH AMERICAN NUCLEAR MEDICINE (MEDICAL) END-USERS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 288

TABLE 107 EUROPEAN NUCLEAR MEDICINE MARKET REVENUE, BY TYPE,

(2014-2022) ($MN) 294

TABLE 108 EUROPEAN NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 295

TABLE 109 EUROPEAN NUCLEAR MEDICINE SPECT MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 296

TABLE 110 EUROPEAN NUCLEAR MEDICINE PET MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 297

TABLE 111 EUROPEAN NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 298

TABLE 112 EUROPEAN NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 299

TABLE 113 EUROPEAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,

BY TYPE, (2014-2022) ($MN) 300

TABLE 114 EUROPEAN NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 301

TABLE 115 EUROPEAN NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE,

BY ISOTOPE, (2014-2022) ($MN) 302

TABLE 116 EUROPEAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,

BY APPLICATION, (2014-2022) ($MN) 303

TABLE 117 EUROPEAN NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS,

(2014-2022) ($MN) 304

TABLE 118 EUROPEAN NUCLEAR MEDICINE (MEDICAL) END-USERS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 305

TABLE 119 ASIA-PACIFIC NUCLEAR MEDICINE MARKET REVENUE, BY TYPE,

(2014-2022) ($MN) 311

TABLE 120 ASIA-PACIFIC NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE,

BY TYPE, (2014-2022) ($MN) 312

TABLE 121 ASIA-PACIFIC NUCLEAR MEDICINE SPECT MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 313

TABLE 122 ASIA-PACIFIC NUCLEAR MEDICINE PET MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 314

TABLE 123 ASIA-PACIFIC NUCLEAR MEDICINE SPECT MARKET REVENUE,

BY APPLICATION, (2014-2022) ($MN) 315

TABLE 124 ASIA-PACIFIC NUCLEAR MEDICINE PET MARKET REVENUE,

BY APPLICATION, (2014-2022) ($MN) 316

TABLE 125 ASIA-PACIFIC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,

BY TYPE, (2014-2022) ($MN) 317

TABLE 126 ASIA-PACIFIC NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 318

TABLE 127 ASIA-PACIFIC NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE,

BY ISOTOPE, (2014-2022) ($MN) 319

TABLE 128 ASIA-PACIFIC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,

BY APPLICATION, (2014-2022) ($MN) 320

TABLE 129 ASIA-PACIFIC NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS, (2014-2022) ($MN) 321

TABLE 130 ASIA-PACIFIC NUCLEAR MEDICINE (MEDICAL) END-USERS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 322

TABLE 131 REST OF THE WORLD NUCLEAR MEDICINE MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 328

TABLE 132 REST OF THE WORLD NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 329

TABLE 133 REST OF THE WORLD NUCLEAR MEDICINE SPECT MARKET REVENUE,

BY ISOTOPE, (2014-2022) ($MN) 330

TABLE 134 REST OF THE WORLD NUCLEAR MEDICINE PET MARKET REVENUE,

BY ISOTOPE, (2014-2022) ($MN) 331

TABLE 135 REST OF THE WORLD NUCLEAR MEDICINE SPECT MARKET REVENUE,

BY APPLICATION, (2014-2022) ($MN) 332

TABLE 136 REST OF THE WORLD NUCLEAR MEDICINE PET MARKET REVENUE,

BY APPLICATION, (2014-2022) ($MN) 333

TABLE 137 REST OF THE WORLD NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 334

TABLE 138 REST OF THE WORLD NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 335

TABLE 139 REST OF THE WORLD NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE, BY ISOTOPE, (2014-2022) ($MN) 336

TABLE 140 REST OF THE WORLD NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN) 337

TABLE 141 REST OF THE WORLD NUCLEAR MEDICINE MARKET REVENUE,

BY END-USERS, (2014-2022) ($MN) 338

TABLE 142 REST OF THE WORLD NUCLEAR MEDICINE (MEDICAL) END-USERS MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 339

TABLE 143 NEW PRODUCT LAUNCHES (2013-2015) 342

TABLE 144 AGREEMENTS, PARTNERSHIP, COLLABORATION & JOINT VENTURES,

(2013-2015) 347

TABLE 145 APPROVALS (2013-2015) 354

TABLE 146 EXPANSIONS (2013-2015) 357

TABLE 147 MERGERS & ACQUISITIONS (2013-2015) 359

TABLE 148 OTHER DEVELOPMENTS (2013-2015) 362

TABLE 149 BAYER HEALTHCARE: TOTAL REVENUE AND R&D EXPENSES,

(2013-2015) ($MN) 364

TABLE 150 BAYER HEALTHCARE: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN) 365

TABLE 151 BAYER HEALTHCARE: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN) 366

TABLE 152 CARDINAL HEALTH, INC.: TOTAL REVENUE AND OPERATING EXPENSES (2013-2015) ($MN) 371

TABLE 153 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENTS,

(2013-2015) ($MN) 372

TABLE 154 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY,

(2013-2015) ($MN) 373

TABLE 155 GENERAL ELECTRIC COMPANY: TOTAL REVENUE AND R&D EXPENSES, (2013 – 2015) ($MN) 385

TABLE 156 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY SEGMENTS,

(2013-2015) ($MN) 386

TABLE 157 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY GEOGRAPHY,

(2013 – 2015) ($BN) 387

TABLE 158 IBA GROUP: TOTAL REVENUE AND R&D EXPENSES (2013 - 2015) ($MN) 394

TABLE 159 IBA GROUP: TOTAL REVENUE, BY SEGMENTS (2013-2015) ($MN) 395

TABLE 160 IBA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2012 – 2014) ($MN) 396

TABLE 161 ISOTEC, INC: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($MN) 402

TABLE 162 ISOTEC, INC: TOTAL REVENUE, BY SEGMENTS (2013-2015) ($MN) 403

TABLE 163 ISOTEC, INC: TOTAL REVENUE, BY GEOGRAPHY (2012-2014) ($MN) 404

TABLE 164 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN) 410

TABLE 165 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY PRODUCTS (2013-2015) ($MN) 411

TABLE 166 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY GEOGRAPHY (2013-2015) ($MN) 412

TABLE 167 MALLINCKRODT PLC: TOTAL SALES AND R&D EXPENSES,

(2013-2015) ($MN) 418

TABLE 168 MALLINCKRODT PLC: TOTAL REVENUE, BY SEGMENTS, (2013- 2015) ($BN) 419

TABLE 169 MALLINCKRODT PLC: TOTAL REVENUE, BY GEOGRAPHY,

(2013- 2015) ($MN) 420

TABLE 170 SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN) 436

TABLE 171 SIEMENS AG: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN) 437

TABLE 172 SIEMENS AG: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN) 438

TABLE 173 TAIYO NIPPON SANSO CORPORATION: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($MN) 444

TABLE 174 TAIYO NIPPON SANSO CORPORATION: TOTAL REVENUE, BY SEGMENTS (2013-2015) ($MN) 445

TABLE 175 TAIYO NIPPON SANSO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2013-2015) ($MN) 446

List Of Figures, Charts and Diagrams
in Nuclear Medicine/Radiopharmaceutical Global Market – Forecast To 2022 [Report Updated: 24-03-2016]

LIST OF FIGURES


FIGURE 1 NUCLEAR MEDICINE GLOBAL MARKET SHARE AND REVENUE, BY REGION, (2014-2022) 38

FIGURE 2 NUCLEAR MEDICINE GLOBAL MARKET: RESEARCH APPROACH 48

FIGURE 3 NUCLEAR MEDICINE GLOBALMARKET: TOP-DOWN AND BOTTOM-UP APPROACH 49

FIGURE 4 NUCLEAR MEDICINE GLOBAL MARKET: FORECASTING MODEL 50

FIGURE 5 NUCLEAR MEDICINE GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION 51

FIGURE 6 NUCLEAR MEDICINE GLOBAL MARKET: MARKET SEGMENTATION 58

FIGURE 7 STABLE ISOTOPES GLOBAL MARKET: MARKET SEGMENTATION 59

FIGURE 8 MARKET DYNAMICS 60

FIGURE 9 NUCLEAR MEDICINE GLOBAL MARKET: PCT PATENT FILING BY MAJOR PLAYERS (2011-2015) 89

FIGURE 10 NUCLEAR MEDICINE GLOBAL MARKET: UNITED STATES PATENT FILING BY MAJOR PLAYERS (2011-2015) 90

FIGURE 11 TECHNETIUM -99: SUPPLY CHAIN ANALYSIS 93

FIGURE 12 NUCLEAR MEDICINE MARKET: PORTER’S ANALYSIS 96

FIGURE 13 NUCLEAR MEDICINE GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015 (%) 99

FIGURE 14 STABLE ISOTOPES MARKET: MAJOR PLAYER ANALYSIS (2015) (%) 102

FIGURE 15 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY TYPE,

(2014-2022) ($MN) 105

FIGURE 16 NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) (%) 107

FIGURE 17 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY ISOTOPE,

(2015 V’S 2022) ($MN) 112

FIGURE 18 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY ISOTOPE,

(2015 V’S 2022) ($MN) 127

FIGURE 19 NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN) 136

FIGURE 20 NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN) 151

FIGURE 21 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN) 160

FIGURE 22 NUCLEAR MEDICINE BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BY ISOTOPE, (2015 V’S 2022) ($MN) 162

FIGURE 23 NUCLEAR MEDICINE BRACHYTHERAPY GLOBAL MARKET REVENUE,

BY ISOTOPE, (2015 V’S 2022) ($MN) 186

FIGURE 24 NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE,

BY APPLICATION, (2015 V’S 2022) ($MN) 198

FIGURE 25 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY END-USERS,

(2014-2022) ($MN) 210

FIGURE 26 STABLE ISOTOPES MARKET: MARKET DYNAMICS 223

FIGURE 27 STABLE ISOTOPES GLOBAL MARKET REVENUE, BY ISOTOPE, (2015) (%) 227

FIGURE 28 STABLE ISOTOPES GLOBAL MARKET REVENUE, BY APPLICATION,

(2015 V’S 2022) ($MN) 241

FIGURE 29 STABLE ISOTOPES GLOBAL MARKET REVENUE, BY GEOGRAPHY,

(2014-2022) ($MN) 251

FIGURE 30 NORTH AMERICAN STABLE ISOTOPES MARKET REVENUE, BY ISOTOPES & APPLICATIONS (2015 V’S2022) ($MN) 254

FIGURE 31 EUROPEAN STABLE ISOTOPES MARKET REVENUE, BY ISOTOPES & APPLICATIONS (2015 V’S 2022) ($MN) 258

FIGURE 32 ASIA-PACIFIC STABLE ISOTOPES MARKET REVENUE, BY ISOTOPES & APPLICATIONS (2015 V’S 2022) ($MN) 262

FIGURE 33 REST OF THE WORLD STABLE ISOTOPES MARKET REVENUE, BY ISOTOPES & APPLICATIONS (2015-2022) ($MN) 266

FIGURE 34 NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 270

FIGURE 35 NORTH AMERICAN SPECT, PET MARKET REVENUE, BY ISOTOPE,

(2015 V’S 2022) ($MN) 274

FIGURE 36 NORTH AMERICAN SPECT, PET MARKET REVENUE, BY APPLICATION,

(2015 V’S 2022) ($MN) 275

FIGURE 37 NORTH AMERICAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY TYPE, BY APPLICATIONS, BETA, BRACHYTHERAPY BY ISOTOPES,

(2015 V’S 2022) ($MN) 276

FIGURE 38 EUROPEAN SPECT, PET MARKET REVENUE, BY ISOTOPE,

(2015 V’S 2022) ($MN) 291

FIGURE 39 EUROPEAN SPECT, PET MARKET REVENUE, BY APPLICATION,

(2015 V’S 2022) ($MN) 292

FIGURE 40 EUROPEAN NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,

BY TYPE, BY APPLICATIONS, BETA, BRACHYTHERAPY BY ISOTOPES,

(2015 V’S 2022) ($MN) 293

FIGURE 41 ASIA-PACIFIC SPECT, PET MARKET REVENUE, BY ISOTOPE,

(2015 V’S 2022) ($MN) 308

FIGURE 42 ASIA-PACIFIC SPECT, PET MARKET REVENUE, BY APPLICATION,

(2015 V’S 2022) ($MN) 309

FIGURE 43 ASIA-PACIFIC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE,

BY TYPE, BY APPLICATIONS, BETA, BRACHYTHERAPY BY ISOTOPES,

(2015 V’S 2022) ($MN) 310

FIGURE 44 ROW SPECT, PET MARKET REVENUE, BY ISOTOPES, (2015 V’S 2022) ($MN) 325

FIGURE 45 ROW SPECT, PET MARKET REVENUE, BY APPLICATIONS,

(2015 V’S 2022) ($MN) 326

FIGURE 46 ROW NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY TYPE,

BY APPLICATIONS, BETA, BRACHYTHERAPY BY ISOTOPES,

(2015 V’S 2022) ($MN) 327

FIGURE 47 KEY GROWTH STRATEGIES (2013 – 2015) 341

FIGURE 48 SWOT: BAYER HEALTHCARE 369

FIGURE 49 SWOT: CARDINAL HEALTH, INC. 378

FIGURE 50 SWOT: CAMBRIDGE ISOTOPE LABORATORIES INC. 383

FIGURE 51 SWOT: GE HEALTHCARE 392

FIGURE 52 SWOT: IBA GROUP 400

FIGURE 53 SWOT: ISOTEC INC 408

FIGURE 54 SWOT: LANTHEUS MEDICAL IMAGING INC. 416

FIGURE 55 SWOT: MALLINCKRODT PLC 424

FIGURE 56 SWOT: NORDION INC 429

FIGURE 57 SWOT: NTP RADIOISOTOPES SOC LTD 434

FIGURE 58 SWOT: SIEMENS HEALTHCARE 442

FIGURE 59 SWOT: TAIYO NIPPON SANSO CORPORATION 451

Additional Details

Publisher

IQ4I

Publisher Information

IQ4I is a global strategy, consulting and a leading market research company. Our clients include leading businesses, investment banks, researchers and government agencies.



We are a team of highly qualified market researchers and consultants, committed to help clients make strategic decisions by providing relevant and firmly reliable data support. We enable our clients to identify the market opportunities with best-in-class market intelligence reports and Business Development & licensing services and provide support in hiring with best talents.

Reference

111553 | Nuclear Medicine/Radiopharmaceutical Global Market Report 24032016

Number of Pages

452

Report Format

PDF

IQ4I Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products
Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclea...
02 Mar 2017 by GBI Research USD $6,995 More Info
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Pipeline Review, H2 2016
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase ...
16 Nov 2016 by Global Markets Direct USD $3,500 More Info
Global Nuclear Imaging Systems Equipment Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 – 2022
The global nuclear imaging system and equipment market is estimated to reach .2 billion by 2022 an...
09 Sep 2016 by Occams Business Research USD $3,900 More Info
Global Nuclear Imaging Systems Equipment Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 – 2022
The global nuclear imaging system and equipment market is estimated to reach .2 billion by 2022 an...
09 Sep 2016 by Occams Business Research USD $5,900 More Info
Diagnostic Imaging: A Market in Transition Amid Regulatory Uncertainty and Intensifying Competition--X-ray, Ultrasound, MRI, CT, Nuclear Medicine, PET, PACS
This new worldwide strategic overview of the diagnostic imaging market includes the following:&middo...
02 Aug 2016 by Venture Planning Group (VPG) USD $3,850 More Info
Diagnostic Imaging: X-Ray, Ultrasound, CT, MRI, PACS, PET, Nuclear Medicine--Modality and Geographic Region Segment Forecasts, Trends and Outlook
A worldwide strategic overview of the diagnostic imaging market, including:Estimates of the market s...
27 Jun 2016 by Venture Planning Group (VPG) USD $2,850 More Info
Nuclear Medicine/Radiopharmaceutical Global Market – Forecast To 2022
Way back to the history, over the past 50 years nuclear medicine sector has displayed a strong link ...
24 Mar 2016 by IQ4I USD $4,500 More Info
Nuclear Medicine/Radiopharmaceutical Global Market – Forecast To 2022
Way back to the history, over the past 50 years nuclear medicine sector has displayed a strong link ...
24 Mar 2016 by IQ4I USD $4,500 More Info
Global Nuclear Medicine Outlook 2020
Nuclear Medicine is one of the most promising segments of the medical imaging industry; and is becom...
01 Dec 2015 by RNCOS USD $2,000 More Info
Refurbished Medical Equipment Market (Ultrasound, MRI, CT Scanner, C-Arm, Nuclear Imaging Systems, Hurt-Lung Machines, Surgical, CO2 Monitor, Patient Monitor, Pulse Oximeter, AED Defibrillator, Cath Labs, Strechers, Endoscopy) - Global Forecasts to 2019
The global refurbished medical equipment market is estimated to grow at a CAGR of 12.5% from 2014 to...
02 Feb 2015 by MarketsandMarkets USD $5,650 More Info

This report is published by IQ4I

IQ4I is a global strategy, consulting and a leading market research company. Our clients include leading businesses, investment banks, researchers and government agencies.

We are a team of highly qualified market researchers and consultants, committed to help clients make strategic decisions by providing relevant and firmly reliable data support. We enable our clients to identify the market opportunities with best-in-class market intelligence reports and Business Development & licensing services and provide support in hiring with best talents.

Download Free Report Summary PDF

Nuclear Medicine/Radiopharmaceutical Global Market  – Forecast To 2022 [Report Updated: 24-03-2016] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)